VIRGINIA BEACH, Va., Jan. 22 /PRNewswire-USNewswire/ -- LifeNet Health, a leading allograft bio-implant company, will nationally launch the CardioGRAFT® decell pulmonary patch with MATRACELL™ technology at the Society of Thoracic Surgeons annual meeting in Ft. Lauderdale, Fla., on January 24.
MATRACELL™ is one of several new and advanced technology platforms that LifeNet Health has developed to enhance the utility and clinical effectiveness of human allograft tissue. MATRACELL™ technology is a patented and validated process to render allograft tissue acellular, removing over 99% of the donor genetic material while retaining the native biomechanical strength of the tissue.
The CardioGRAFT® decell pulmonary patch with MATRACELL™ technology is currently being implanted in four clinical centers that specialize in correcting life threatening pediatric congenital heart conditions. The sites will be generating data regarding clinical results for publication and presentation.
Surgeons will be able to discuss clinical experience and the science behind MATRACELL™ Technology at the Society of Thoracic Surgeons annual meeting with Richard Hopkins, MD, Director, Cardiac Surgery Research Laboratories Chief, Adolescent/Adult Congenital Cardiac Surgery Professor of Surgery, UMKC at Children's Mercy Hospitals and Clinics Kansas City, MO, and Alyce Linthurst Jones, Ph.D., LifeNet Health Research and Development Project Manager in Virginia Beach, VA.
"We are excited to offer MATRACELL™ to surgeons across the country to help restore health to pediatric heart patients. MATRACELL™ has the potential to improve clinical outcomes and increase implant durability. We hope this will reduce the number of surgeries any child will have to undergo with this improved technology," said Rony Thomas, LifeNet Health CEO and President.
The Society of Thoracic Surgeons is a not-for-profit organization representing more than 5,800 surgeons, researchers, and allied health professionals worldwide.
LifeNet Health has a long history of unsurpassed safety and quality with more than two million bio-implants distributed, including 20,000 cardiovascular allografts without any disease transmission. All allograft tissue undergoes a multi-step quality assurance review that exceeds the standards set by both the FDA and American Association of Tissue Banks (AATB).
LifeNet Health, a non-profit global leader in regenerative medicine, is the world's largest provider of bio-implants and organs for transplantation whose mission is saving lives and restoring health by advancing the field of tissue engineering.
For additional information about LifeNet Health, visit www.lifenethealth.org.
SOURCE LifeNet Health
Advertisement
MATRACELL™ is one of several new and advanced technology platforms that LifeNet Health has developed to enhance the utility and clinical effectiveness of human allograft tissue. MATRACELL™ technology is a patented and validated process to render allograft tissue acellular, removing over 99% of the donor genetic material while retaining the native biomechanical strength of the tissue.
Advertisement
The CardioGRAFT® decell pulmonary patch with MATRACELL™ technology is currently being implanted in four clinical centers that specialize in correcting life threatening pediatric congenital heart conditions. The sites will be generating data regarding clinical results for publication and presentation.
Surgeons will be able to discuss clinical experience and the science behind MATRACELL™ Technology at the Society of Thoracic Surgeons annual meeting with Richard Hopkins, MD, Director, Cardiac Surgery Research Laboratories Chief, Adolescent/Adult Congenital Cardiac Surgery Professor of Surgery, UMKC at Children's Mercy Hospitals and Clinics Kansas City, MO, and Alyce Linthurst Jones, Ph.D., LifeNet Health Research and Development Project Manager in Virginia Beach, VA.
"We are excited to offer MATRACELL™ to surgeons across the country to help restore health to pediatric heart patients. MATRACELL™ has the potential to improve clinical outcomes and increase implant durability. We hope this will reduce the number of surgeries any child will have to undergo with this improved technology," said Rony Thomas, LifeNet Health CEO and President.
The Society of Thoracic Surgeons is a not-for-profit organization representing more than 5,800 surgeons, researchers, and allied health professionals worldwide.
LifeNet Health has a long history of unsurpassed safety and quality with more than two million bio-implants distributed, including 20,000 cardiovascular allografts without any disease transmission. All allograft tissue undergoes a multi-step quality assurance review that exceeds the standards set by both the FDA and American Association of Tissue Banks (AATB).
LifeNet Health, a non-profit global leader in regenerative medicine, is the world's largest provider of bio-implants and organs for transplantation whose mission is saving lives and restoring health by advancing the field of tissue engineering.
For additional information about LifeNet Health, visit www.lifenethealth.org.
SOURCE LifeNet Health
